Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Inclusion Criteria:

• Must have completed study CN012-0026, CN012-0027 or CN012-0056.

• Subject was aged 55 to 90 years, inclusive, at the time of enrollment into theparent CN012-0026, CN012-0027 or CN012-0056 study.

• Can understand the nature of the study and protocol requirements and provide asigned informed consent or, if deemed not competent to provide informed consent, thesubject's legally acceptable representative must provide informed consent, and thesubject must provide informed assent before any study assessments are performed.

• At entry into this study, or any time during the study, if a subject needs torelocate from home or residential assisted-living facility to a nursing homefacility, the Sponsor/Medical Monitor must approve the subject's participation inthe study.

• Have an identified or proxy caregiver (spends approximately 10 hours/week with thesubject).

Exclusion Criteria:

• Significant or severe medical conditions that, in the opinion of the Investigator,could jeopardize the safety of the subject, ability to complete or comply with thestudy procedures or validity of the study results.

• Clinically significant abnormalities, including any finding(s) from the ECG,laboratory tests, physical examination, or vital signs, at the EOT visit of StudyCN012-0026, CN012-0027 or CN012-0056 that the Investigator, in consultation with theMedical Monitor, are considered to jeopardize the safety of the subject.

• Subjects participating in another investigational drug or device study or planningon participating in another clinical study during the duration of CN012-0028.

• Other protocol-defined Inclusion/Exclusion criteria apply.